



December 26, 2018
TRANS GENIC INC.
(Code No.2342 TSE Mothers)

Patent on Monoclonal Antibody against Novel Lung Cancer Marker and Diagnostic Application thereof has been Decided to Grant in Japan

TRANS GENIC INC. (CEO: Kenji Fukunaga, Fukuoka City, Fukuoka, Japan) hereby announces that, the decision to grant the patent on a monoclonal antibody against splice variant of α -actinin-4 and its diagnostic application have been delivered by Japan Patent Office. TRANS GENIC and National Cancer Center (President: Dr. Hitoshi Nakagama, Chuo-ku, Tokyo, Japan) jointly filed the international patent application on this technology on September 9, 2011 (PCT/JP2011/071168).

【Overview】

The new tumor marker, splice variant of α -actinin-4, was discovered by Dr. Kazufumi Honda (Laboratory Head, Department of Biomarkers for Early Detection of Cancer, National Cancer Center Research Institute) and Dr. Tesshi Yamada (Visiting Scientist, Division of Cellular Signaling, National Cancer Center Research Institute). It is useful for diagnosis of small-cell lung cancer. This patent application is related to the antibody against this tumor marker which is produced by GANP® mouse technology. This antibody enables to improve the detection rate of this tumor marker in small lung cancer patients, and increase the diagnostic accuracy.

The patent on this technology has already been granted in the United States.

TRANS GENIC will work toward the practical use of this antibody, such as licensing to the companies manufacturing simple detection system useful for the diagnosis of small lung cancer, as part of monetization of the intellectual properties.

This patent acquisition will not have a material impact on the business result or financial performance for the fiscal year 2018. TRANS GENIC will promote the development of biomarker antibody and the enhancement of protein-related technology platform for the future growth of earnings.

◆Reference: Small-cell lung cancer

Small-cell lung cancer accounts for 20% of total lung cancer. Since it is the most progressive lung cancer, and detected as advanced cancer with metastatic tumors of multiple organs in most cases, it is considered as one of the malignant diseases with poor prognosis. Therefore, there is a strong unmet need for the improvement in diagnostic accuracy in early-stage.

GANP® Mouse technology

GANP (Germinal Center Associated Nuclear Protein) is a nuclear factor which is upregulated in B-cells in germinal center. GANP® Mouse technology is an antibody-developing technology utilizing GANP® mice in which GANP gene is overexpressed. Antibodies generated by GANP® mice, characteristic for their high affinity and high specificity, are applicable for diagnostic agents and antibody

therapeutics.

Contact for inquiries and additional information :
TRANS GENIC INC.
Yutaka Funabashi, Director
Telephone +81-(0)3-6551-2601